This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chamberlain, N. et al. Rituximab does not reset defective early B cell tolerance checkpoints. J. Clin. Invest. http://dx.doi.org/10.1172/JCI83840
Rights and permissions
About this article
Cite this article
Greenhill, C. Effects of anti-B-cell therapy. Nat Rev Endocrinol 12, 64 (2016). https://doi.org/10.1038/nrendo.2015.234
Published:
Issue date:
DOI: https://doi.org/10.1038/nrendo.2015.234